At IgGenix, our mission is to develop a first-in-class therapy for millions of people whose daily lives are limited by food allergies and other severe allergic conditions.
Starting from a deep understanding of molecular immunology, we employ our SeqSifter™ antibody-based therapeutic discovery platform to potentially enable faster, deeper and more sustained clinical responses. We push the limits of single-cell genomic technology to capture and analyze very rare human B cells expressing allergen binding antibodies. We engineer these antibodies to uniquely capture allergens and endow them with powerful immune modulating activities derived from the IgG antibody class to suppress allergic reactions. Our team is at work today to make this new life changing therapy tomorrow’s reality.
Latest News
August 19, 2022
How Re-Engineering Antibodies Can Prevent Allergies (Labiotech.eu)
July 1, 2022
IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies
April 26, 2022
IgGenix Announces Move of Headquarters to Lilly Gateway Labs in South San Francisco
February 23, 2022
July 27, 2021
June 24, 2021
IgGenix Announces Jessica Grossman, M.D., as Chief Executive Officer
The IgGenix Team
MANAGEMENT
Jessica Grossman, M.D
Chief Executive Officer
Henry Lowman, Ph.D.
Chief Scientific Officer
Derek Croote, Ph.D.
Chief Technical Officer
SCIENTIFIC CO-FOUNDERS
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Biohub
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.
Stanford University
BOARD OF DIRECTORS
Jessica Grossman, M.D
IgGenix
Samir Kaul
Khosla Ventures
Joel S. Marcus
Alexandria Real Estate Equities, Inc. / Alexandria Venture Investments
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Biohub
Mattias Westman
Prosperity Capital Management
SCIENTIFIC ADVISORY BOARD
Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I. (Chairperson)
Stanford University
Hans Oettgen, M.D., Ph.D.
Harvard Medical School
Stephen Quake, D. Phil.
Stanford University; Chan Zuckerberg Biohub
Scott Smith, M.D., Ph.D.
Vanderbilt University
Dale Umetsu, M.D., Ph.D.
Stanford University; University of California, San Francisco
Jim Wells, Ph.D.
University of California, San Francisco
Publications
- Croote, D. et al, “IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies” Presented at 2022 EAACI Hybrid Congress
- Croote, D. et al, “Unbiased Single Cell Sequencing of IgE-Producing B Cells Yields High-Affinity Human Antibodies to the Cat Allergen Fel d 1” Presented at PEGS 2022 Annual Meeting
- Croote, D. et al, “Blood from Highly Allergic Donors Yields High-Affinity IgE Antibodies to Food and Non-food Allergens” Presented at AAAAI 2022 Annual Meeting
- Croote D. et al, “Longitudinal Analysis of Single B Cells, IgE Antibodies, and Plasma in a Peanut Allergic Subject” Presented at ACAAI 2021 Annual Meeting.
- Croote D. et al, “Monoclonal IgE antibodies reengineered as food allergy therapeutics” Presented at EAACI Congress 2021.
Investors
Careers
We are a small, innovative and passionate team working in a fast-paced environment at the forefront of allergy immunology. We have exciting opportunities for enthusiastic, self-motivated, and detail-oriented individuals to join the growing team at IgGenix. IgGenix offers competitive compensation, comprehensive benefits, equity, and the opportunity for growth.
Scroll through our list of open positions and apply today!
For more information contact us at HR@IgGenix.com.
Current Job Opportunities
IgGenix is a rapidly growing company. Please check back for available positions soon.
Contact
IgGenix, Inc
681 Gateway Blvd., Floor 4
South San Francisco, CA 94080
650-491-9626
info@IgGenix.com